Traditionally, breast cancer therapies have relied on categorizing the disease into subtypes, determined by the presence of certain proteins, such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast carcinoma.